Ann: Mayne Pharma to restate US dermatology net revenue for FY22, page-42

Almost every post you make has had NO consideration of the downside. This includes you ramping it all the way from above $4.50 (equivalent) - to $3.00. If you are going to do some research (which doesn't include licking a finger and pointing it in the air) - then post that research and help others make more balanced or informed decisions.

You only have to read some market commentary to see why MYX is priced the way it is; especially after purchasing a set of drugs (whose seller was in administration - that's how profitable they have been). We have NOTHING left from the MCS sale; see below. We paid the debt facility and are still waiting for news about a new debt facility. And we were burning cash faster than Zimbabwe were printing it in the 2010's!

MYX desperately need (or needed) to strip out costs. Need to rein in the spending for Nextstellis despite making an additional $20m allowance (on top of a $40m loss ouch).

On top of above; we've also admitted to banking revenue incorrectly which appears like an attempt to ensure we didn't breach lending covenants!!

We have results coming out in a few days which will smashing the current carrying value of the company as the ridiculously optimistic Goodwill levels are returned to levels reflective of the performance of the company - this will smash the existing $417m.

Great time to buy.... Ummm. It is true that risk = reward, but anyone who ignored your advice pre dividend is already 50% better off.